RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 144 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,655,952 | +2.4% | 8,451,758 | 0.0% | 14.74% | +14.7% |
| Q2 2023 | $63,134,635 | +12.0% | 8,451,758 | 0.0% | 12.84% | +19.5% |
| Q1 2023 | $56,373,229 | -13.5% | 8,451,758 | 0.0% | 10.75% | -16.4% |
| Q4 2022 | $65,163,057 | -27.5% | 8,451,758 | 0.0% | 12.86% | -20.6% |
| Q3 2022 | $89,927,000 | +30.7% | 8,451,758 | 0.0% | 16.21% | +20.5% |
| Q2 2022 | $68,798,000 | +591.9% | 8,451,758 | +508.5% | 13.46% | +595.4% |
| Q1 2022 | $9,944,000 | -58.2% | 1,388,889 | 0.0% | 1.94% | -57.5% |
| Q4 2021 | $23,792,000 | – | 1,388,889 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |